Nilotinib, Inhibitor
Nilotinib (AMN-107)
Purity
>99%
Synonyms
Nilotinib; Nilotinib (AMN-107); inhibitor
Purity/Purification
>99%
Solubility
DMSO >=12mg/mL - Water <1mg/mL - Ethanol <1mg/mL
Formula
C28H22F3N7O
CAS Number
641571-10-0
Preparation and Storage
Store at-20 degree C 2 years.
Testing Data
Related Product Information for Nilotinib, inhibitor
Chronic myelogenous leukaemia (CML) and Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL) are caused by the BCR-ABL oncogene. AMN107 inhibited the proliferation of Ba/F3 cells expressing p210-and p190-Bcr-Abl, or K562 and Ku-812F cells with IC50 values <12 nM. AMN107 was quantitatively via capture ELISA for its effect on cellular Bcr-Abl autophosphorylation activity and on Bcr-Abl-dependent cell proliferation. AMN107, IC50 =20-60 nM.[1] The effects of AMN107 were compared with those of imatinib on imatinib-sensitive (KBM5 and KBM7) and imatinib-resistant CML cell lines (KBM5-STI571R1.0 and KBM7-STI571R1.0). Compared with the antiproliferative activity of imatinib, AMN107 was 43times more potent in KBM5 (IC50 of 11.3 versus 480.5 nM) and 60 times more potent in KBM7(IC50 of 4.3versus 259.0 nM) cells. IC50 for AMN107 and imatinib were 2, 418.3 and 6, 361.4 nM, respectively, in KBM5-STI571R1.0, and 97.2 and 2, 497.3nM, respectively, in KBM7-STI571R1.0 cells.[2]
Product Categories/Family for Nilotinib, inhibitor
